Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2014, Article ID 945620, 5 pages
Clinical Study

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme

1Department of Radiation Oncology, North Coast Cancer Institute, Coffs Harbour, NSW, Australia
2Rural Clinical School Faculty of Medicine, University of New South Wales, NSW, Australia
3Department of Radiation Oncology, North Coast Cancer Institute, Lismore, NSW, Australia
4Department of Radiation Oncology, North Coast Cancer Institute, Port Macquarie, NSW, Australia
5Faculty of Medicine, University of Sydney, NSW, Australia

Received 9 April 2013; Revised 14 October 2013; Accepted 16 October 2013; Published 19 January 2014

Academic Editor: Mamede de Carvalho

Copyright © 2014 Noel J. Aherne et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. Glioblastoma multiforme (GBM) is optimally treated by maximal debulking followed by combined chemoradiation. Intensity modulated radiation therapy (IMRT) is gaining widespread acceptance in other tumour sites, although evidence to support its use over three-dimensional conformal radiation therapy (3DCRT) in the treatment of gliomas is currently lacking. We examined the survival outcomes for patients with GBM treated with IMRT and Temozolomide. Methods and Materials. In all, 31 patients with GBM were treated with IMRT and 23 of these received chemoradiation with Temozolomide. We correlated survival outcomes with patient functional status, extent of surgery, radiation dose, and use of chemotherapy. Results. Median survival for all patients was 11.3 months, with a median survival of 7.2 months for patients receiving 40.05 Gray (Gy) and a median survival of 17.4 months for patients receiving 60 Gy. Conclusions. We report one of the few series of IMRT in patients with GBM. In our group, median survival for those receiving 60 Gy with Temozolomide compared favourably to the combined therapy arm of the largest randomised trial of chemoradiation versus radiation to date (17.4 months versus 14.6 months). We propose that IMRT should be considered as an alternative to 3DCRT for patients with GBM.